Sunnyvale, United States
CellMax Life, founded in 2013, is positioned at the forefront of the biotechnology and health care industries with its innovative focus on liquid biopsy technology for cancer screening. Their proprietary platform is tailored to detect pre-cancer and cancer cells, disrupting traditional diagnostic paradigms by offering globally affordable, non-invasive tests.
With its unique expertise in both Circulating Tumor Cell and Next Generation Sequencing of DNA and circulating tumor DNA (ctDNA), CellMax Life has developed effective precision medicine solutions that cater to both healthy individuals and cancer patients. Headquartered in the United States, the company's mission is to transform the landscape of cancer diagnosis and management.
The last injection of funds was a Series C investment on 23 March 2021, with backing from investors such as Artiman Ventures, iD Ventures America, and Aflac Global Ventures. This financial support underscores the high confidence in their pioneering mission and technological capabilities.
On-Q-ity